These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 27203715)

  • 1. Rosuvastatin slows progression of subclinical atherosclerosis in patients with treated HIV infection.
    Longenecker CT; Sattar A; Gilkeson R; McComsey GA
    AIDS; 2016 Sep; 30(14):2195-203. PubMed ID: 27203715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short Communication: The Effect of Rosuvastatin on Vascular Disease Differs by Smoking Status in Treated HIV Infection.
    Hileman CO; McComsey GA
    AIDS Res Hum Retroviruses; 2018 Mar; 34(3):282-285. PubMed ID: 28974102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial.
    Crouse JR; Raichlen JS; Riley WA; Evans GW; Palmer MK; O'Leary DH; Grobbee DE; Bots ML;
    JAMA; 2007 Mar; 297(12):1344-53. PubMed ID: 17384434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of statin on arginine metabolites in treated HIV-infection.
    Dirajlal-Fargo S; El Kamari V; Sattar A; Alam K; Funderburg N; Labbato D; Pirro L; Longenecker CT; Wilson WH; McComsey GA
    Atherosclerosis; 2017 Nov; 266():74-80. PubMed ID: 28992467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin therapy decreases N-terminal pro-B-type natriuretic peptide in HIV: randomized placebo-controlled trial.
    Dirajlal-Fargo S; Kinley B; Jiang Y; Longenecker CT; Hileman CO; Debanne S; McComsey GA
    AIDS; 2015 Jan; 29(3):313-21. PubMed ID: 25686680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of atherosclerosis in patients living with HIV.
    De Lorenzo F; Boffito M; Collot-Teixeira S; Gazzard B; McGregor JL; Shotliff K; Xiao H
    Vasc Health Risk Manag; 2009; 5(1):287-300. PubMed ID: 19436663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in oxidized lipids drive the improvement in monocyte activation and vascular disease after statin therapy in HIV.
    Hileman CO; Turner R; Funderburg NT; Semba RD; McComsey GA
    AIDS; 2016 Jan; 30(1):65-73. PubMed ID: 26731754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot randomized trial comparing an intensive versus a standard intervention in stable HIV-infected patients with moderate-high cardiovascular risk.
    Masiá M; Bernal E; Padilla S; García N; Escribano JC; Martínez E; Gutiérrez F
    J Antimicrob Chemother; 2009 Sep; 64(3):589-98. PubMed ID: 19625372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of rosuvastatin on plasma coenzyme Q10 in HIV-infected individuals on antiretroviral therapy.
    Morrison JT; Longenecker CT; Mittelsteadt A; Jiang Y; Debanne SM; McComsey GA
    HIV Clin Trials; 2016 Jul; 17(4):140-6. PubMed ID: 27294339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-year treatment with rosuvastatin reduces carotid intima-media thickness in HIV type 1-infected patients receiving highly active antiretroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular risk.
    Calza L; Manfredi R; Colangeli V; Trapani FF; Salvadori C; Magistrelli E; Danese I; Verucchi G; Serra C; Viale P
    AIDS Res Hum Retroviruses; 2013 Mar; 29(3):547-56. PubMed ID: 23098891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label).
    Braamskamp MJAM; Langslet G; McCrindle BW; Cassiman D; Francis GA; Gagne C; Gaudet D; Morrison KM; Wiegman A; Turner T; Miller E; Kusters DM; Raichlen JS; Martin PD; Stein EA; Kastelein JJP; Hutten BA
    Circulation; 2017 Jul; 136(4):359-366. PubMed ID: 28592434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Markers of inflammation and CD8 T-cell activation, but not monocyte activation, are associated with subclinical carotid artery disease in HIV-infected individuals.
    Longenecker CT; Funderburg NT; Jiang Y; Debanne S; Storer N; Labbato DE; Lederman MM; McComsey GA
    HIV Med; 2013 Jul; 14(6):385-90. PubMed ID: 23332012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosuvastatin preserves renal function and lowers cystatin C in HIV-infected subjects on antiretroviral therapy: the SATURN-HIV trial.
    Longenecker CT; Hileman CO; Funderburg NT; McComsey GA
    Clin Infect Dis; 2014 Oct; 59(8):1148-56. PubMed ID: 25015912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study.
    Bots ML; Palmer MK; Dogan S; Plantinga Y; Raichlen JS; Evans GW; O'Leary DH; Grobbee DE; Crouse JR;
    J Intern Med; 2009 Jun; 265(6):698-707. PubMed ID: 19298496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial.
    Lo J; Lu MT; Ihenachor EJ; Wei J; Looby SE; Fitch KV; Oh J; Zimmerman CO; Hwang J; Abbara S; Plutzky J; Robbins G; Tawakol A; Hoffmann U; Grinspoon SK
    Lancet HIV; 2015 Feb; 2(2):e52-63. PubMed ID: 26424461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV vasculopathy: role of mononuclear cell-associated Krüppel-like factors 2 and 4.
    Hale AT; Longenecker CT; Jiang Y; Debanne SM; Labatto DE; Storer N; Hamik A; McComsey GA
    AIDS; 2015 Aug; 29(13):1643-50. PubMed ID: 26372274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of cardiovascular disease in a cohort of HIV-infected adults: a study using carotid intima-media thickness and coronary artery calcium score.
    Mangili A; Gerrior J; Tang AM; O'Leary DH; Polak JK; Schaefer EJ; Gorbach SL; Wanke CA
    Clin Infect Dis; 2006 Dec; 43(11):1482-9. PubMed ID: 17083026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of 96 Weeks of Rosuvastatin on Bone, Muscle, and Fat in HIV-Infected Adults on Effective Antiretroviral Therapy.
    Erlandson KM; Jiang Y; Debanne SM; McComsey GA
    AIDS Res Hum Retroviruses; 2016 Apr; 32(4):311-6. PubMed ID: 26477698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of two intensive statin regimens on progression of coronary disease.
    Nicholls SJ; Ballantyne CM; Barter PJ; Chapman MJ; Erbel RM; Libby P; Raichlen JS; Uno K; Borgman M; Wolski K; Nissen SE
    N Engl J Med; 2011 Dec; 365(22):2078-87. PubMed ID: 22085316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study).
    Calza L; Magistrelli E; Colangeli V; Borderi M; Bussini L; Bon I; Re MC; Viale P
    Infect Dis (Lond); 2017 Oct; 49(10):737-747. PubMed ID: 28683645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.